Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Polycystic Ovary Syndrome 2Skin Diseases 1Sarcoma 1Rare Diseases 1Neoplasms 1Lymphoma 1Hematologic Neoplasms 1Endocrine System Diseases 1Breast Neoplasms 1Advanced Malignant Neoplasm 1Acanthosis Nigricans 1

Interventions

Ocoxin 2niraparib 1anlotinib 1Thalidomide 1Sunitinib 1Spironolactone 1Paclitaxel 1Melphalan 1Leuprolide 1Filgrastim 1Etoposide 1Doxorubicin 1Dexamethasone 1Cyclophosphamide 1Cisplatin 1Carboplatin 1Calcium Dobesilate 1CP protocol 1Bortezomib 1Bevacizumab 1Ascorbic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Endocrine System Diseases × Spironolactone × Clear all
NCT00004311 2005-06-24

Phase II Study of the Effect of Leuprolide Acetate and Spironolactone on Insulin Resistance in Hyperandrogenic Women With Polycystic Ovarian Disease or Hyperandrogenism Insulin Resistance Acanthosis Nigricans Syndrome

Office of Rare Diseases (ORD)

Phase 2 Completed

Acanthosis Nigricans, Endocrine System Diseases, Polycystic Ovary Syndrome, Skin Diseases, Rare Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡